Right. Okay. I was rather hoping to see everybody's faces. Yeah. Clearly today we're not going to be able to do that. A big welcome. We'll kick off. My instructions are to say that if you want to ask some questions, if you go into the Q&A box and flag that you've got questions, rather than asking the questions on that box, and then when we get to the end, Gemma will unmute your line, and you'll be able to ask your question then. Hopefully that makes sense. Use the Q&A box and to flag that you want to ask a question, and we'll come back to you and unmute lines and hopefully answer any questions that you might have. Okay. You're very welcome to the Animalcare full year results presentation. Myself and Chris will be talking you through the results. No great surprises after our trading update, and you'll have seen more of the information this morning. Hopefully what we can do today is just to give a little bit more flavor and a little bit more commentary about the numbers and some of the things that we've been doing. I'll kick off with hopefully a slide change. Okay. Having looked down the list of people attending and the participants in the meeting, I think many of you have talked to either myself or Chris or been part of these sessions before. Some of you many times, and some of you a few times. I think most people will be aware that we've focused on five key things for the last two and a half years, really. What we'll do today is talk you through our progress against these five. We have stuck to them throughout what we're calling the challenging year in terms of the pandemic. Strong finances has been a real focus for us, and this is about making sure that our finances are in good shape so that we can invest in future growth. You'll have seen from the RNS, and you will see through the presentation, we're very focused on cash conversion and net debt, both of those are going in the right direction. Leadership, we recognized in the last couple of years how important leadership was going to be to the success of Animalcare moving forward, and really happy with the results from our Gallup Q12 survey, and we've got an 11% improvement. That's pretty cool. We're very proud of that. We've put in place a new structure. Then the next three are really about our business, our portfolio, and what are we doing there. We split this into three areas. The growth portfolio, which is really, we think of that as our existing business, the business that we have today, and really making sure that we focus that. We'll talk a little bit more about that. Making sure that we're focused on higher margin brands. Business development, really to drive our future. Many of you will know because we talked about it at the interims STEM deal, which is targeting biofilm diseases, is now reality and we've strengthened our BD capability, and really made sure that we focus there. We'll talk about that. One of the most exciting things that has happened for us, and actually it was in early 2021, was the Committee for Medicinal Products for Veterinary Use gave a positive opinion for our exciting new novel product, Daxocox. That is a really important milestone and very exciting for us. We are initiating more pipeline projects. We'll talk you through a little bit more detail. What I'll do first is to hand over to Chris to talk you through the financial highlights. Hi. Morning, everyone. Sorry I can't see you, it's a bit strange. As Jenny said, we've had a really resilient year, and we'll come onto more detail. Before we start on covering some of these highlights, I just thought we'd kind of talk about the kind of shape of 2020, in particular, the kind of H1 and H2 dynamic in terms of the pandemic. Just to kind of recap, we entered 2020 in a strong financial position, as we've said before. We've had an overall resilient revenue and profit performance despite the kind of challenging conditions and another year of strong cash generation. In terms of the shape of 2020, so to recap at the half year, revenues were down around 4%, and that really reflected the significant disruption in Q2 after a strong quarter 1. EBITDA was broadly flat, largely due to action taken to defer or reduce spend. Debt and EBITDA leverage ratios were roughly in line with 2019. One area to note was that cash conversion at the half year was significantly lower than expected, and that was largely due to stock build. We turn now to the full financial year. We saw year-on-year revenue growth in H2 of around 3%, so that follows the pattern of recovery in our Companion Animal business. Cash conversion significantly improved since the first half, which has led, as Jenny noted, to another material reduction in net debt. That means that we're better placed than we've ever been to fund our growth ambitions. We move on to the headlines on the slide. Obviously all the relevant numbers and detail can be found in the press release. We'll pick up just at the highlight level. Revenue down 0.9%. We'll provide more detail on the next slide, but we've seen, as with the first half, varying impacts on our markets, both in terms of country and the product category performance, with Companion Animal seeing a greater impact of COVID versus the Production Animal. Underlying EBITDA was down 8% to GBP 12.1 million, with a corresponding reduction in EBITDA margin. We saw a modest drop in gross profit. A bit pleasingly, gross margins held firm despite the higher percentage of revenues from our lower-margin Production Animal portfolio. As we execute the strategy, coupled with the strong market fundamentals and the resilient trading performance, we've become increasingly confident about our future. Hence, despite the challenges on the revenue line, we've continued to invest in the business and future growth. That's in particular in the areas of sales and marketing excellence, STEM, and most significantly, Daxocox. We're really excited about those two opportunities. For Daxocox, we recognize that we'll be operating in what we describe as the Champions League in terms of potential competitors. Hence, we've invested appropriately in advance of these expected launches in the current year, with the objective of driving uptake during the second half of this year and further sales growth in 2022 and beyond. That investment led to SG&A costs as a percentage of revenue increasing by 1%- 35%. Actually notably, that overall level investment is what we'd expected to invest notwithstanding the pandemic. Cash conversion, another excellent year here. Exceeded 100% of our EBITDA, really demonstrating our ability to deliver strong and sustainable levels of cash. Overall levels of working capital were broadly the same versus 2019. The GBP 1.6 million inventory is largely strategic stock build now in advance of manufacturing transfers. Really, we saw a good reduction in H2. The supply chain team have done a really good job in reducing the stock build we observed in H1. That increase in stock is balanced by other trade working capital movements. Net debt, this is down GBP 4.2 million- GBP 13.6 million, largely driven by the cash conversion. Our EBITDA leverage was around 1.1x at the end of the year. You'll have seen in the press release that we've continued this momentum post year-end, providing us with even more capacity to invest in growth. Finally on the dividend. Reflecting the resilient performance in 2020, continued strong cash generation and confident outlook, and that outlook confidence is kind of reflecting in part what we're seeing in terms of the encouraging start to 2021. The board proposed a final dividend of GBP 0.02 per share, and that gives a total dividend for the year of GBP 0.04. If we move on to slide 5, more color on revenue here. As I said, the performance reflects the varying market and portfolio dynamics across the operations, with the overall resilient trading picture, as I mentioned, driven by the balance of those two dynamics. We'll touch on Companion Animals first. That was 3.6% down in revenue terms, and that compares to a 11% reduction at the half year, and as I said earlier, reflects the recovery in certain of our markets during the second half. If we view country performance against this backdrop, we can see, as at the half year again, the most significant decline in the U.K. This is where the portfolio in the U.K. is all Companion Animals. What we saw here in quarter 2 was more severe disruption and impact of COVID on the customer base, where in particular, the corporates were subject to large-scale closures of veterinary practices. The Companion Animal business in Benelux also saw double-digit decline. That was largely observed in the OTC portfolio and vaccine product range. The former was COVID driven, and the latter was given by a novel competitor launch. We contrast this to Germany, which was up 4% on last year. The market data was all saying that around three quarters, maybe even more, of veterinary practices remained open and continued to operate in normal. There, that's just reflected in the performance. Italy continued to perform really well. Just over 30% increase in 2020 on the back of 20% growth in 2019. That was largely driven by the Companion Animals portfolio there, in particular, sales of annualized products that we launched in 2019. Really pleasing performance there. Just to note, we've said before about Germany and Italy, really good businesses, but small in a very large market. Absolutely remain focused on scaling up both of those operations over the next three to five years. If you contrast Companion Animal performance to Production Animals, which this year accounts for 28% of the sales, so higher than normal. This was less affected by COVID, hence the growth we've seen. That growth was largely driven by Spain and Italy. With the increase in Spain helping to offset some of the further distributor de-stocking we saw at the end of 2020, which is contributing in part to the Q1 strong performance that I noted earlier. Just very briefly on network partners, as you can see on there, it grew strongly in the year. That was largely driven by new product launches and more significantly, customer stock build in advance of either manufacturing transfers or cessation of contracts. We are going to see some unwind of that growth in 2021. Slide 6. As we commented in all recent presentations, the financial strength underpins our ability to, and capacity to invest and strengthen the platform and future growth opportunities. In this slide, we just wanted to show here that it demonstrates how our continuing focus on sound financial discipline, largely observed through the above 100% average cash conversion in the last two years, has led to a halving of our debt since the end of 2017. We're at or around now the lower end of our target leverage range, which is 1x-2x EBITDA, which means we're in a really good position to increase investment over the next years. Jenny will come on to some of that area, including continued and further investment in Daxocox and STEM. Pipeline CapEx for information in 2020 was GBP 1.7 million. We're expecting to increase that in 2021 and double that as a percentage of sales in 2022 to deliver on the opportunity available to us. Just a brief note on banking facilities, which you maybe picked up. We've almost completed the renewal of our facilities with the four syndicate banks. The objective there was to extend the term from March 2022 to March 2025, and we expect to finalize that process in the next week or so. Just to summarize. Looking forward into 2021, it's clear we're seeing evidence of a recovery in our markets with, as I've said in my CFO report, a marked increase in revenues versus the same period in 2020. Remembering that that was a pre-pandemic period where we did actually see strong growth on 2019. We're still early in the financial year, so obviously there are some uncertainties around, in particular COVID remaining. I think we can take confidence from not only the strong start to the year, but also the kind of learnings and dynamics we've seen in the market in terms of how our business, the veterinary profession, et cetera, has learned to live with the virus. Also take confidence from the planned launches from Daxocox and STEM. Together with a strong balance sheet and opportunities available to us, I think that the execution of our strategy since 2018 will become more evident in financial performance in the next couple of years. That's me. Back to you, Jenny. Thanks. Okay. If I could change the slide. I feel a bit like the COVID press briefing. I don't seem to be able to change slide at the moment. Strange, isn't it? Aha. Okay, hopefully the magic has happened for everyone else, and here we are. You'd think after a year that this would be just seamless, wouldn't it? Being able to change slides, mute and unmute, and see everybody, hey. As you know, the second pillar that we talk about and we're really focused on is advancing our leadership agenda. Really when you reflect on 2020 and the performance, the financial performance that Chris has talked about, I'm absolutely convinced that that was driven because we've got some great leaders in place now. I can look at the organization and think we've got a great team. Actually, I also am really proud of the fact that we redid the Gallup survey at the end of 2020, our improvement year-on-year was up by 11%. Given that some of the teams had to completely change the way that they worked, they were working from home, dealing with all of those issues that we've all been facing around kids and dogs and COVID and all of those things. I think this result is great. More people participated. Chris talked about the first quarter, and when I look at the performance, clearly our team is becoming better, building capabilities and as they build and as we get better working as one team, you can feel the increase in motivation. Recognizing that all of the work that we do to get to that financial stability, get the team in place, sort out the portfolio is really, that kind of is a tick in the box. Recognizing that our strategy is all about future growth. One of the things that we did, actually in February, was restructured the business to make sure that we're really fit for that future growth and that our structure is aligned. Some of you who we've talked to previously know that I ran a completely flat structure because as I say to the teams, it enabled me to be nosy into everything. The time has come where we really need to focus on the priorities. For us, the three priorities are making sure that we deliver on our existing business. That's priority number 1. In order to do that, we've put in place a north and a south structure with a regional director. That's really about performance management day-to-day, delivering on our expectations, but also reducing duplication, et cetera. When you look at our business, and Chris talks about production animal and companion animal, we've got a really clear split. The south, so Spain, Italy, Portugal, is a mixed business. There's production animal and companion animal. The north is almost entirely a companion animal business. There's different challenges facing those groups. Corporates and the ways that vet work are different in the north than in the south. One of the things I thought was fascinating was when we looked at data about vets' willingness to see our reps. The south are desperate to have the reps back in visiting them. They want that face-to-face. In the north, it's a little bit more, "Mm, maybe when the time's ready." A bit more conservative about that. We've set up that structure, north and south, which is great, and it gave a good opportunity for one, the head of the south is a lady called Maria, who's been with the organization for about three years. The head of the north is a gentleman called Bernhard Putz, who we actually brought in to head up Germany in September. He comes, both of those individuals have great experience from big pharmaceutical companies in this field. The other thing that we've done is our second priority is to make sure that we're really building that future portfolio and growth portfolio. We're recruiting for somebody to be the head of our product and business development organization. One of our opportunities is that we've got some great products that are now part of our business. Daxocox and STEM. Also we're looking for external opportunities to continue to build that pipeline and balancing and prioritizing that portfolio is going to be really important. That new structure includes business development and product development to really drive that future growth. Then, of course, financial strength. Chris and his team continue to make sure that we have that financial strength. That new organization structure is done. It's gone very well. The final point on this slide is the time had come to make sure we all looked the same, because we still had a lot of different branding around the different countries, and we had a lot of different logo styles, et cetera. We've now implemented the new branding in March, and it builds on our heritage. What we've done is taken a pragmatic view of the group and said, "Look, if you are Ecuphar in Spain and you've built a really good reputation, let's not change you to Animalcare, but let's look the same." We're now all aligned in terms of look and feel with sort of a one family approach, but we haven't changed names where the name was established. There's another practical reason for that. We have lots of marketing authorizations, and all of those need to change, which takes time and money. The new style is now out there, and it's getting some good feedback, and it all adds to that motivation and employee engagement that we're seeing in the Gallup survey as well, people feeling about the future of this business and the excitement. We talk about our existing portfolio, and I just wanted to share with you a couple of things that demonstrate what we've been doing here. On the left-hand side, we've got about 200 brands. We had about 330 brands at the time of the merger in 2017. We've been really reducing those. Actually what we're starting to see is that the growth is starting to come from the big brands. 71% of our revenues come from the top 40 brands, and they're growing at 3.2% year-on-year. We're starting to see this move towards a smaller number of higher selling, higher margin products. It's a reality. We will continue to take products that aren't really driving revenue, that have a lower margin or less profitable. We'll continue to take those out of the tail. We've sort of set ourselves a target of about 150. I don't know that there's a right and wrong answer of how many brands should we have, but that feels like the right sort of number. We're gradually moving products from right to left effectively on this visual. Just in contrast, if you look at what we had at the merger, whilst 63% of revenues from the top 40 selling brands is not that far off the 71%. The really important thing, and the challenge that we had at the time was 14% of revenues were generated by the smallest 236 brands. Complexity, fragmentation, all of those things was quite significant. This is an ongoing process, but really improving the quality and the shape of portfolio. One of the things that several of you will have heard me say before is that we've set ourselves criteria for anything that comes into our portfolio, and it has to be up in that top 10 level. Our top products are around the GBP 3.5 million-GBP 4 million. What we're looking for is to bring products into that level. You gradually move that. The bigger brands become bigger, and we gradually take off the tail. That's work in progress but has really made an impact, and we're starting to see some really nice growth. This is our exciting area, Daxocox and STEM. Daxocox, whenever I've spoken to you before, we've always called it E6087, apart from every so often, I accidentally said Daxocox. It feels really nice to be able to talk about Daxocox. We're really excited about this. We're expecting the EU marketing authorization middle of April. That's up to the CVMP, exactly when that happens. We're all very actively planning for launch in the second half of 2021, hopefully earlier in the second half. We're a bit dependent on when the final authorization comes through. We've extended the geographic reach beyond those countries where we're directly selling and marketing it ourselves through some partnerships. In terms of what this product represents, it represents two things. One is this marketplace, which is sort of chronic acute pain, osteoarthritis-type pain. In Europe, the segment is worth about GBP 130 million, and it's growing. Daxocox is differentiated. Whenever we talk to key opinion leaders, they're very excited about this product. Really for us, this is real, it's ours, it's patent protected, all of those good things. Now it's down to us to execute. We, as Chris said, we've been investing in making sure that our sales and marketing teams are ready to go, that we have the right sort of support. We're hoping to compete really effectively with some of the Premier League players and teams or the Champions League. This is really exciting. I think the second reason why this is exciting for us is it demonstrates that we can do what we've set out to do in terms of our strategy. We can develop a product. We ran all the clinical studies on this. We do all the regulatory filings, et cetera. It demonstrates that we can do it. I think this is why the organization is so fired up for success. The other thing that the positive opinion has given us is the confidence to really invest in future life cycle management projects. Additional indications, different areas of pain, different formulations, tablets, injectables, et cetera, but also starting to do the work that we need to do to be able to register the product in other territories around the world. Some are easy to do because they accepted European license. Some we need to do some more work. As Chris mentioned, our R&D spend will be increasing, about 50% of that increase in R&D will be to fund either Daxocox or a smaller amount to fund some new pipeline development on STEM Animal Health. That's relatively low risk because we know that both of these are successful technologies. We are planning in 2022, just thinking ahead, to deliver on pipeline opportunities, particularly around Daxocox and STEM Animal Health. Our investment will go up, but in really good quality. A few words on STEM Animal Health. We talked, I think, a lot at the interims, and we've been talking about this. We're planning to launch the first of the biofilm products, which will be the dental products in Q4. We're currently transferring manufacturing from North America to Europe, which is really important for us to make sure we have a robust supply chain. Since September, we've looked at all the other opportunities for pipeline projects, and we're particularly focused on otitis, so ear infections, and that, again, some of the R&D investment will be funding those. The other part of the R&D investment is really linked to some of the business development activities that we are engaging in at the moment to bring products at different stages from different companies into our pipeline. The other part of the R&D budget will fund some of those opportunities that we will be bringing in in the next few months. Just summarizing, and then we can go to questions. I see Mike's already got his hand up for a question. Overall, look, it's been a really resilient performance in the face of pandemic. We're pleased with where we got to. I think we've had so many uncertainties, but the teams really responded extremely well. Cash generation continues to be good, continuing reduction in net debt, and both of those are really giving us the increased capacity to invest in growth. As I mentioned, we've got lots of exciting discussions going on and lots of exciting things to do with our pipeline with Daxocox and STEM. Really making progress on all fronts. It feels very much like a very different business to where we were even last year. So we're really moving forward. Just to reiterate what Chris was talking about, encouraging quarter on revenues well ahead of 2020, which was a pre-COVID, so it's a really good indicator. We're expecting to return to revenue growth this year. Normal trading, whatever that looks like, despite COVID going on, we're pretty confident that we'll be able to weather any future storms that may come. As Chris said, our finances are just getting stronger. For us, the real focus is growth. Where do we go next? What are the opportunities and really making a success out of Daxocox and STEM. I'm going to stop there and maybe Gemma, you can. There's I think a couple of people, both Max and Mike. I don't know who'd like to go first. Gemma, can you open up Mike's? You might be muted yourself. There you are. Yeah. Am I unmuted now? Yes, you are. Yeah, that's me, Mike. Super. Good to see you this morning, Jenny and Chris. I just wondered on Daxocox, if you could elaborate on the present IP estate as it stands and how you'd anticipate that developing in due course. I'm just thinking about what that indicates for your strategy for future commercialization of the product beyond Europe. Yeah. The patent status is we've got strong patents everywhere. We own the patent, and it's a pretty long basic patent. Obviously one of the things we'll do is make sure that we make the most of any new data that we use for regulatory data protection and make sure that we have a very robust patent strategy. The basic patent has a long life ahead of it anyway, so we're pretty confident there. Got it. In terms of the EPO, the European Patent Office, I've seen that running through to 2034, so I presume that- Yeah ..the reference. Okay. Yeah. Great. Yes. Just thinking about your life cycle comments, would you be looking for exactly the same indication or sets of indications for Daxocox in all markets? Are there certain nuances or additional opportunities you've particularly got your eye on now that you've got this first positive opinion in the bag? Yeah. If you look at the products that we'll be competing against, our first indication is in that sort of chronic, acute chronic pain area. This is a once-a-week product, so that's a really good thing if you've got a chronic treatment. We'll be looking at new indications around pain, acute and chronic, things like postoperative pain, et cetera. What we'll try and do is, or in fact, what we've got in the development plan is building an extension of indications, so different areas of pain and different formulations, so looking at bigger tablets. The other thing we're looking at is different species. Yeah. We've got different species in the plan. It's a pretty comprehensive development plan, looking at all of those things, trying not to fragment it so that we have one indication there, one indication somewhere else. We probably will have a slightly different approach in the U.S. just because the U.S. market is a bit different around these sorts of products. Yeah. Other than that, we'll try and make sure that we have indications that are aligned globally because that will really help to build a strong brand. Yeah. That's fantastic. Thanks, Jenny. Cheers. Okay. I think Max wanted a question there. Hey. Hello, Jenny. Hi, Max. Morning, Max. Sorry. Double press to unmute. Thanks for taking my questions. Actually, if I may, firstly, just a little bit more detail on the current trading. You alluded to, obviously it's a period comparison versus no COVID with a little bit of stocking, I believe, ahead of the lockdowns this time last year. You also mentioned that there was some inventory restocking in Spain in the first quarter this year. I just wondered how that normalizes. If there's any more color you can give on the performance and whether there's companion animal versus food-producing or production animals bias in that. Yeah. The destocking point, there was a bit of destocking in 2019 versus 2020 as well, so that's relatively normalized. I think it was a continuing trend of the Spanish business in the market kind of returning to what we would see as normalized levels versus what we see in other countries. I think there's a little bit of impact there. In terms of the dynamics, there's absolutely a return to what we've seen in terms of pattern of companion animals growing very strongly versus production animals. Both categories growing, but companion animals growing stronger than production animals. That's the trajectory or the kind of shape of that Q1. Okay. Just on the manufacturing and the transfer of that to Europe, how's that process progressing, and what's that involve? A bit more detail on that and a little bit on timing as well. Sure. At the moment, the dental products for STEM, which is where we're referencing the manufacturing transfer, are made in North America. What we do is we take the file that gives all the details of how to make them, and we did effectively a review of available manufacturing around Europe, and we have chosen the site and the transfer is in progress. Our new site is talking to the North American site to make sure that they get everything aligned and everything is good and ready to go. That's a very active process at the moment. It's all about validating the process, checking it, doing lots of quality assurance and quality control, and that's all going very well. We're very comfortable with that. It'll take us another probably six months to finalize all of that just because it's a new manufacturing site. That really makes it much more robust for us rather than shipping products in from North America, and it's much more agile as well. Okay. Just a couple other small, really related to Daxocox and what you call sales and marketing excellence. On the Daxocox rollout. You've obviously talked a bit about splitting your marketing and the way you look at it into North and South territories and how they behave differently. Is there a rollout plan where you introduce those? I know in pharma, you're usually introducing places like Germany, U.K., those type of northern territories first, perhaps, and southern later. Is there anything like that to be aware of in how Daxocox gets rolled out? Yeah. What are your key selling messages? Just on the sales and marketing excellence, what are you actually doing there? Are you investing in new sales reps or are you training or what's going on? Yeah. You're right. With human pharmaceuticals, there's usually a rollout plan, often driven actually by pricing. We don't have that same challenge because veterinary medicines are free price. The other thing that drives that rollout plan is usually the amount of time it takes for the individual member states to approve the packaging. That is just a fairly local bureaucracy type thing. U.K. and Germany are usually the quickest. They just happen to be. We think with Daxocox, we're using standard packaging across all the teams, it'll look and feel the same. We think that we should have a fairly small gap between first launch and last launch. We're aiming to get them all off the ground as quickly as we can, starting, we hope, early in the second half. You shouldn't see that big spread that you sometimes see in human pharmaceuticals. Fingers crossed. From our side, there's nothing stopping us. It's much more about local regulation on packaging. In terms of how we're doing the Sales and Marketing Excellence, this is something that we started in 2020. We were very clear that for something like Daxocox, we needed to build some capabilities, build a strong team. We brought in last year, some really good sales and marketing people to work at the group level. For the last year, actually, we've been running a group. The group has been running with representatives from each of the countries, the whole Sales and Marketing Excellence program. We've done lots of marketing training. We've got brand plans in place. We've got everything's aligned in terms of messaging, which I won't share today because it's competitive sensitive. We've got all the message tested and we're ready to go. In terms of sales, the sales force, what we've spent some time doing is looking at, in our countries, what's the best go-to-market model, and whether it's the same representatives selling both the existing portfolio and the new portfolio, or whether actually we need some different skills. That's a bit more driven by the local customer type set up. In the U.K. where you've got corporates, we've put in place a really strong key account manager together with a technical vet to talk to the corporates about the clinical effectiveness of Daxocox. In Germany, where it's much more of an individual sales rep talking to an individual customer, we are increasing the capability of our sales teams through training, but also bringing in some people who are used to selling these sorts of products. It's a bit of a mix of organic growth, development, training, and a few people that we've brought in. There's a very clear Sales and Marketing Excellence process running. That includes all the communications, key opinion leader, advisory boards. As I said, all the packaging is the same across all the countries, all the materials look the same and have the same feel. That's in pretty good shape. Almost ready to go on the day of launch as soon as we get the label. Yeah. People have really responded well to it, Max. Okay. Great. Thank you. Have we got anybody else? I think that's the only questions that we have currently. Don't know if anyone else has got any questions they want to pop on the Q&A screen. If not, I think we're done. Unless anybody has anything else, I shall thank you all very much for attending. As always, funnel all your questions through. More than happy if we've missed something or you've got other questions to address those. Other than that, I shall stop sharing and finish the meeting. There's one final check. Hang on. No more questions. Thanks. Thank you very much. Thanks, everyone.